Endurance shuttle walking test: responsiveness to salmeterol in COPD

Area of Science:

• Pulmonary Medicine
• Exercise Physiology

Background:

• The endurance shuttle walking test (ESWT) shows potential for evaluating treatment responsiveness in chronic obstructive pulmonary disease (COPD).
• Further investigation is needed to establish the ESWT's utility in assessing daily living activity improvements in COPD patients.

Purpose of the Study:

• To assess the responsiveness of the ESWT in detecting improvements in walking performance after a single dose of salmeterol in COPD patients.
• To evaluate the impact of salmeterol on cardiorespiratory parameters, lung function, and perceived dyspnea during the ESWT.

Main Methods:

• A randomized, double-blind, placebo-controlled crossover trial involving 20 COPD patients.
• Patients performed two ESWT sessions at 80% peak capacity, 2.5 hours post-inhalation of either placebo or 50 mcg salmeterol.
• Monitoring included cardiorespiratory parameters, inspiratory capacities, and Borg ratings for dyspnea.

Main Results:

• Salmeterol significantly improved lung function and walking performance (117±20 s longer, 160±277 m further) compared to placebo.
• A significant reduction in dyspnea was observed at isotime after salmeterol administration.
• Salmeterol effectively reduced dyspnea and enhanced walking capacity during the ESWT.

Conclusions:

• Single-dose salmeterol improves walking capacity and reduces dyspnea in COPD patients.
• The ESWT is a responsive and valuable tool for evaluating bronchodilator effects on exercise performance in COPD.
• Findings support the ESWT's role in assessing functional improvements relevant to daily activities in COPD management.